Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering)

重组抗CTLA-4全人源单克隆抗体（华兰基因工程）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRecombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering)
Drug Alias Name重组抗CTLA-4全人源单体注射液重组抗CTLA-4全人源单克隆抗体注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHualan Ankang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A